Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)

Charité University Medicine Berlin logo

Charité University Medicine Berlin

Status and phase

Completed
Phase 3
Phase 2

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Treatments

Drug: Olanzapine

Study type

Interventional

Funder types

Other

Identifiers

NCT00876772
OLN-ALS01

Details and patient eligibility

About

Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon. As a result of motor neurodegeneration, a progredient paralysis of the extremities and of the speaking, swallowing, and breathing musculature develops. ALS leads to death by respiratory insufficiency in a mean course of 3-5 years. More than 80% of ALS patients present with a clinically significant and undesirable weight loss. The cause of weight loss is heterogeneous. Fundamentally, the investigators must distinguish malnutrition, cachexia and loss of appetite. Loss of weight is an independent prognosis factor in ALS. Effective treatment of undesirable weight loss is an important therapy goal for ALS. The researchers propose an investigational therapy of ALS with oral administration of Olanzapine. The rationale for this study is based on the weight-increasing effect of OLN. The clinical trial aims to employ OLN-induced weight gain or weight stabilization as a symptomatic therapy for the loss of appetite. An undesired weight loss of at least 10% of the body weight should be reduced through the weight-increasing effect of OLN. The hypothesis states that the undesired weight loss in ALS patients during treatment with OLN 10mg in combination with Riluzole (RIL) 100mg is at least 20 percentage points less than for treatment with placebo in combination with 100 mg RIL.

Full description

After randomization, there is a placebo-controlled parallel group treatment with 10 mg OLN in combination with the standard treatment of Riluzole (100mg/day)(Group 1) in comparison to treatment with placebo in combination with 100 mg RIL (Group 2). Study drug will be provided as 5 mg tablets. OLN will be begun in an initial dosage of 5 mg/day for one week. The intake will occur in the evening hours in the form of a capsule containing 5 mg OLN. The evening dose of Riluzole can be taken together with the OLN medication. After one week (day 8), the dose will be increase to 10 mg OLN/day, which will be taken in the form of two capsules at the same timepoint in the evening hours. This dose will be continued for 51 weeks.

Enrollment

40 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients between the ages of 18 and 80 years old
  • Clinical diagnosis of definitive, probable, and possible ALS (revised El Escorial Criteria) or diagnosis of the clinical ALS-variants of Progressive Muscle Atrophy (PMA)
  • Sporadic and familial ALS
  • Beginning of symptoms of paralysis at least 6 months prior
  • Treatment with a steady dose of RIL 100 mg/day for at least 1 month
  • A score of ≤ 28 in the symptom-oriented Council on Nutrition appetite questionnaire (CNAQ) by which appetite is evaluated
  • Patient consent

Exclusion criteria

  • Patients with known hypersensitivity to OLN, RIL, or one of the active ingredients
  • Percutaneous Endoscopic Gastronomy (PEG)
  • Clinically significant eating disorder
  • Deliberate weight loss
  • Underlying consumptive disease with undesired weight loss
  • Overweight with BMI ≥ 25 kg/m2
  • Clinically significant hypotonia and history of recurrent syncopes (> 1 syncope)
  • Clinically severe concomitant illnesses, including psychiatric illnesses
  • Pregnant or nursing women
  • Severe neutropenia (< 750/mm3)
  • Open angle glaucoma
  • Diabetes mellitus
  • Prostatic hyperplasia
  • Extrapyramidal movement disorders including from late dyskinesia
  • Dementia and incompetence to grant informed consent
  • Clinically significant EKG changes
  • EKG proof of a QT time corrected according to Fridericia (QTcF) > 500 ms
  • Treatment with substances that are metabolized by the Cytochrom-P450-System CYP1A2 (e. g. Carbamazepine, Fluvoxamin, and Ciprofloxacin)
  • Treatment with Mirtazapine within the past 3 months
  • Treatment with steroids or appetite-stimulating substances including anabolics within the past 3 months
  • Treatment with Valproat within the past 3 months
  • Treatment with hepatotoxic medicines
  • Treatment with tetrahydrocannabinol within the past 3 months
  • Treatment with another atypical or typical neuroleptic within the past 3 months
  • Treatment with any other study medication < 1 month before the beginning of the study
  • Destructive use of psychotropic substances within the past 3 months
  • Destructive use of alcohol
  • Laboratory parameters outside the normal range that are associated with a clinically significant cardiovascular, pulmonologic, hematologic, hepatological, metabolic, or renal disease or that interfere with interpretation of the clinical study or that require medications that are not permitted in the study protocol
  • Elevation of the serum transaminase levels (ALT/AST) to more than 3-times of the upper normal value
  • Elevation of the bilirubin and gamma glutamyl transferase levels (GGT) to beyond the maximum normal value
  • History of a cardiopulmonary reanimation und prevention of sudden cardiac death
  • History of clinically significant EKG changes
  • History of thrombotic events including deep leg vein thrombosis and pulmonary artery embolism
  • History of a paralytic ileus
  • History of epilepsy or an episodic seizure

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Central trial contact

Thomas Meyer, MD; Teresa Holm, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems